Cargando…

Benefit–Risk Profile of Sphingosine-1-Phosphate Receptor Modulators in Relapsing and Secondary Progressive Multiple Sclerosis

Since the approval of fingolimod, several selective sphingosine-1-phosphate receptor modulators have entered clinical development for multiple sclerosis. However, side effects can occur with sphingosine-1-phosphate receptor modulators. By considering short-term data across the drug class and longer...

Descripción completa

Detalles Bibliográficos
Autores principales:	Comi, Giancarlo, Hartung, Hans-Peter, Bakshi, Rajesh, Williams, Ian M., Wiendl, Heinz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2017
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5661009/ https://www.ncbi.nlm.nih.gov/pubmed/28905255 http://dx.doi.org/10.1007/s40265-017-0814-1

Ejemplares similares

An update on the use of sphingosine 1-phosphate receptor modulators for the treatment of relapsing multiple sclerosis
por: Dumitrescu, Laura, et al.
Publicado: (2023)

The Benefits and Risks of Switching from Fingolimod to Siponimod for the Treatment of Relapsing–Remitting and Secondary Progressive Multiple Sclerosis
por: Vališ, Martin, et al.
Publicado: (2023)

Effect of the sphingosine-1-phosphate receptor modulator ozanimod on leukocyte subtypes in relapsing MS
por: Harris, Sarah, et al.
Publicado: (2020)

Autoimmunity to Sphingosine-1-Phosphate-Receptors in Systemic Sclerosis and Pulmonary Arterial Hypertension
por: Gluschke, Hans, et al.
Publicado: (2022)

Interaction of microRNAs with sphingosine kinases, sphingosine-1 phosphate, and sphingosine-1 phosphate receptors in cancer
por: Xu, Guangmeng, et al.
Publicado: (2021)

The role of sphingosine‐1‐phosphate in inflammation and cancer progression
por: Nagahashi, Masayuki, et al.
Publicado: (2018)

Modulation of Specific Sphingosine-1-Phosphate Receptors Augments a Repair Mediating Schwann Cell Phenotype
por: Schira-Heinen, Jessica, et al.
Publicado: (2022)

The Role of Sphingolipids and Sphingosine-1-phosphate—Sphingosine-1-phosphate-receptor Signaling in Psoriasis
por: Masuda-Kuroki, Kana, et al.
Publicado: (2023)

Survival benefit of sphingosin‐1‐phosphate and receptors expressions in breast cancer patients
por: Lei, Fu‐Ju, et al.
Publicado: (2018)

Central Modulation of Selective Sphingosine-1-Phosphate Receptor 1 Ameliorates Experimental Multiple Sclerosis
por: Musella, Alessandra, et al.
Publicado: (2020)

Relapse-independent multiple sclerosis progression under natalizumab
por: Graf, Jonas, et al.
Publicado: (2021)

Sphingosine 1-Phosphate and Atherosclerosis
por: Kurano, Makoto, et al.
Publicado: (2018)

Effects of High‐ and Low‐Fat Meals on the Pharmacokinetics of Ozanimod, a Novel Sphingosine‐1‐Phosphate Receptor Modulator
por: Tran, Jonathan Q., et al.
Publicado: (2017)

Identification of targets and new developments in the treatment of multiple sclerosis – focus on cladribine
por: Warnke, Clemens, et al.
Publicado: (2010)

Sphingosine-1 phosphate promotes thymic atrophy during sepsis progression
por: Kuchler, L, et al.
Publicado: (2014)

Sphingosine 1-Phosphate Receptor Modulators and Drug Discovery
por: Park, Soo-Jin, et al.
Publicado: (2017)

Sphingosine Kinase 1 and Sphingosine-1-Phosphate Signaling in Colorectal Cancer
por: Bao, Yonghua, et al.
Publicado: (2017)

Reduced sphingosine kinase-1 and enhanced sphingosine 1-phosphate lyase expression demonstrate deregulated sphingosine 1-phosphate signaling in Alzheimer’s disease
por: Ceccom, Johnatan, et al.
Publicado: (2014)

Elevated Serum Levels of Arachidonoyl-lysophosphatidic Acid and Sphingosine 1-Phosphate in Systemic Sclerosis
por: Tokumura, Akira, et al.
Publicado: (2009)

Sphingosine 1-Phosphate Receptor 1 as a Useful Target for Treatment of Multiple Sclerosis
por: Chiba, Kenji, et al.
Publicado: (2012)

Targeting Sphingosine-1-Phosphate Signaling in Immune-Mediated Diseases: Beyond Multiple Sclerosis
por: Pérez-Jeldres, Tamara, et al.
Publicado: (2021)

Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis
por: Cree, Bruce AC, et al.
Publicado: (2020)

Efficacy and safety of ocrelizumab in patients with relapsing‐remitting multiple sclerosis with suboptimal response to prior disease‐modifying therapies: A primary analysis from the phase 3b CASTING single‐arm, open‐label trial
por: Vermersch, Patrick, et al.
Publicado: (2021)

Dihydro-sphingosine 1-phosphate interacts with carrier proteins in a manner distinct from that of sphingosine 1-phosphate
por: Mishima, Yuko, et al.
Publicado: (2018)

Irisin Is Target of Sphingosine-1-Phosphate/Sphingosine-1-Phosphate Receptor-Mediated Signaling in Skeletal Muscle Cells
por: Pierucci, Federica, et al.
Publicado: (2023)

Pharmacological Approaches to Delaying Disability Progression in Patients with Multiple Sclerosis
por: Wiendl, Heinz, et al.
Publicado: (2015)

Sphingosine Kinases/Sphingosine-1-Phosphate and Death Signalling in APP-Transfected Cells
por: Gassowska, Magdalena, et al.
Publicado: (2014)

Characterizing Sphingosine Kinases and Sphingosine 1-Phosphate Receptors in the Mammalian Eye and Retina
por: Porter, Hunter, et al.
Publicado: (2018)

Sphingosine Kinases and Sphingosine 1-Phosphate Receptors: Signaling and Actions in the Cardiovascular System
por: Cannavo, Alessandro, et al.
Publicado: (2017)

Onset of secondary progressive multiple sclerosis is not influenced by current relapsing multiple sclerosis therapies
por: Coret, Francisco, et al.
Publicado: (2018)

Cytoplasmic sphingosine-1-phosphate pathway modulates neuronal autophagy
por: Moruno Manchon, Jose Felix, et al.
Publicado: (2015)

Sphingosine‐1‐Phosphate Modulates the Effect of Estrogen in Human Osteoblasts
por: Tantikanlayaporn, Duangrat, et al.
Publicado: (2018)

Sphingosine-1-Phosphate: Its Pharmacological Regulation and the Treatment of Multiple Sclerosis: A Review Article
por: Cohan, Stanley, et al.
Publicado: (2020)

Correction to: Targeting Sphingosine-1-Phosphate Signaling in Immune-Mediated Diseases: Beyond Multiple Sclerosis
por: Pérez-Jeldres, Tamara, et al.
Publicado: (2021)

Sphingosine‐1‐phosphate improves outcome of no‐reflow acute myocardial infarction via sphingosine‐1‐phosphate receptor 1
por: Polzin, Amin, et al.
Publicado: (2022)

Optical Control of Sphingosine-1-Phosphate Formation and Function
por: Morstein, Johannes, et al.
Publicado: (2019)

Sphingosine kinase and sphingosine-1-phosphate regulate epithelial cell architecture by the modulation of de novo sphingolipid synthesis
por: Santacreu, Bruno Jaime, et al.
Publicado: (2019)

Sphingosine 1-phosphate Receptor Modulator Therapy for Multiple Sclerosis: Differential Downstream Receptor Signalling and Clinical Profile Effects
por: Chun, Jerold, et al.
Publicado: (2020)

Commentary: The sphingosine kinase 1/sphingosine-1-phosphate pathway in pulmonary arterial hypertension
por: Bhavanam, Naga P., et al.
Publicado: (2015)

Flotillin proteins recruit sphingosine to membranes and maintain cellular sphingosine-1-phosphate levels
por: Riento, Kirsi, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_jlteuevmo8mj1pccg03cstt11i